Module 6 Writing AssignmentAlemtuzumabis a naked monoclonal antibody used for the targeted attack of CD52 antigens found on the surface of T and B cells. 1.Mechanism of action. Alemtuzumab binds to the CD52 antigens leading to increased cytokine levels in the blood and the lysis of T and B lymphocytes. Since CD52 antigens are found in both malignant and normal lymphocytes, the drug leads to an overall reduction in B and T lymphocytes in the body. The depletion of immune cells by Alemtuzumab is dose-dependent. The administration of a high concentration of the drug results in a higher depletion of B and T cells. Unlike other mechanismsused by the monoclonal antibodies to fight cancers, Alemtuzumab binds and marks a target on the affected immune cells making them visible for other immune cells. 2.Molecular TargetAlemtuzumab is derived via recombinant DNA technology and humanized to target human CD52 antigens. It targets all cells presenting with the CD52 antigen but majorly attacks T and B lymphocytes because of the high concentration of CD52 on their surfaces.